#Blood Screening Market size

[latestmarketresearchnews]

Blood Screening Market Size, Share & Trends Analysis Report By 2030

The global blood screening market was valued at USD 3.40 billion in 2024, and it is expected to grow at a compound annual growth rate (CAGR) of 11.9% from 2025 to 2030. The market's rapid expansion is primarily driven by the increasing number of blood donations worldwide, which necessitates stringent screening protocols to ensure the safety of blood and detect transfusion-transmissible infections. This growth is further fueled by advancements in technology, particularly in automation and molecular platforms, which enhance the accuracy and efficiency of blood screening processes. Additionally, the rising prevalence of infectious diseases, combined with government initiatives aimed at promoting blood safety, is contributing to the market's upward trajectory. Growing public awareness about the importance of safe blood transfusions also plays a key role in market growth.

Blood screening is a critical medical procedure that involves analyzing blood samples to detect various health conditions and abnormalities. It provides vital insights into an individual's health, allowing for the early detection, prevention, and management of diseases. The screening process typically involves evaluating blood cell counts, identifying infectious agents like viruses and bacteria, and measuring levels of chemicals such as cholesterol and glucose. The significance of blood screening lies in its ability to help healthcare professionals identify potential health problems before symptoms appear. This is crucial in diagnosing conditions like anemia, diabetes, infections, and cardiovascular diseases.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Technological advancements continue to improve the precision and efficiency of blood screening methods. At the same time, increasing awareness about the importance of early disease detection promotes the adoption of preventive healthcare measures. Another contributing factor to the market's growth is the aging global population, which is associated with a higher prevalence of diseases that require blood screening. Rising healthcare expenditures around the world also support the adoption of advanced technologies and services in the blood screening field. Together, these factors drive the ongoing growth and evolution of the blood screening market, highlighting its essential role in proactive healthcare strategies aimed at improving patient outcomes and public health.

Product Segmentation Insights:

In 2024, reagents led the blood screening market, accounting for the largest revenue share of 73.4%. Reagents are critical components in diagnostic tests, providing the chemical, biological, or immunological substances required to trigger specific reactions that yield accurate test results. The growing demand for highly specific and precise blood analyses has driven the development of innovative reagent formulations that enhance the performance of diagnostic tests. Reagents are also cost-effective, making them widely accessible, which contributes to their dominant market position.

The instruments segment is expected to experience the fastest growth, with a projected CAGR of 10.8% over the forecast period. This growth is attributed to technological advancements and the increasing demand for reliable diagnostic solutions. Modern blood screening instruments are designed to improve both accuracy and efficiency, addressing the need for rapid diagnostics in healthcare settings. Innovations such as high-throughput analyzers and point-of-care testing devices have improved the usability and accessibility of blood testing. Despite challenges such as high costs and the reusable nature of some devices, continuous technological development is expected to drive sustained growth in this segment. Healthcare providers are increasingly seeking dependable and efficient tools for blood analysis, and the advancements in instruments are expected to meet these evolving needs.

In summary, the global blood screening market is poised for strong growth due to factors such as increasing blood donations, technological innovations, rising healthcare expenditures, and greater public awareness. The market will continue to evolve, driven by a combination of product developments in reagents and instruments, along with a growing focus on preventive healthcare and early disease detection.

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

[researchreportinsight]

Blood Screening Industry Size & Share | Statistics Report 2030

The global blood screening market was valued at USD 3.40 billion in 2024, and it is expected to grow at a compound annual growth rate (CAGR) of 11.9% from 2025 to 2030. The market's rapid expansion is primarily driven by the increasing number of blood donations worldwide, which necessitates stringent screening protocols to ensure the safety of blood and detect transfusion-transmissible infections. This growth is further fueled by advancements in technology, particularly in automation and molecular platforms, which enhance the accuracy and efficiency of blood screening processes. Additionally, the rising prevalence of infectious diseases, combined with government initiatives aimed at promoting blood safety, is contributing to the market's upward trajectory. Growing public awareness about the importance of safe blood transfusions also plays a key role in market growth.

Blood screening is a critical medical procedure that involves analyzing blood samples to detect various health conditions and abnormalities. It provides vital insights into an individual's health, allowing for the early detection, prevention, and management of diseases. The screening process typically involves evaluating blood cell counts, identifying infectious agents like viruses and bacteria, and measuring levels of chemicals such as cholesterol and glucose. The significance of blood screening lies in its ability to help healthcare professionals identify potential health problems before symptoms appear. This is crucial in diagnosing conditions like anemia, diabetes, infections, and cardiovascular diseases.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Technological advancements continue to improve the precision and efficiency of blood screening methods. At the same time, increasing awareness about the importance of early disease detection promotes the adoption of preventive healthcare measures. Another contributing factor to the market's growth is the aging global population, which is associated with a higher prevalence of diseases that require blood screening. Rising healthcare expenditures around the world also support the adoption of advanced technologies and services in the blood screening field. Together, these factors drive the ongoing growth and evolution of the blood screening market, highlighting its essential role in proactive healthcare strategies aimed at improving patient outcomes and public health.

Product Segmentation Insights:

In 2024, reagents led the blood screening market, accounting for the largest revenue share of 73.4%. Reagents are critical components in diagnostic tests, providing the chemical, biological, or immunological substances required to trigger specific reactions that yield accurate test results. The growing demand for highly specific and precise blood analyses has driven the development of innovative reagent formulations that enhance the performance of diagnostic tests. Reagents are also cost-effective, making them widely accessible, which contributes to their dominant market position.

The instruments segment is expected to experience the fastest growth, with a projected CAGR of 10.8% over the forecast period. This growth is attributed to technological advancements and the increasing demand for reliable diagnostic solutions. Modern blood screening instruments are designed to improve both accuracy and efficiency, addressing the need for rapid diagnostics in healthcare settings. Innovations such as high-throughput analyzers and point-of-care testing devices have improved the usability and accessibility of blood testing. Despite challenges such as high costs and the reusable nature of some devices, continuous technological development is expected to drive sustained growth in this segment. Healthcare providers are increasingly seeking dependable and efficient tools for blood analysis, and the advancements in instruments are expected to meet these evolving needs.

In summary, the global blood screening market is poised for strong growth due to factors such as increasing blood donations, technological innovations, rising healthcare expenditures, and greater public awareness. The market will continue to evolve, driven by a combination of product developments in reagents and instruments, along with a growing focus on preventive healthcare and early disease detection.

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

[marketresearchreportinsight]

Blood Screening Industry Analysis And Segment Forecast till 2030

The global blood screening market was valued at USD 3.40 billion in 2024, and it is expected to grow at a compound annual growth rate (CAGR) of 11.9% from 2025 to 2030. The market’s rapid expansion is primarily driven by the increasing number of blood donations worldwide, which necessitates stringent screening protocols to ensure the safety of blood and detect transfusion-transmissible…

[industrynewsupdates]

Blood Screening Market Outlook and Forecast Report, 2030

The global blood screening market is expected to reach USD 6.62 billion by 2030, registering a CAGR of 11.7% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to the increase in screening of donor and continuous technological advancement by the market players. Demand for blood screening tests is increasing continuously due to increasing donation, rising awareness about transfusion-transmitted diseases, and technological developments in the industry. Furthermore, governments of various countries are in process to mandates testing all donated blood for several viruses.

Thorough screening is necessary for all donated blood to ensure that recipients receive the safest products. As of 2015, such testing consists of screening for red cell antibodies, and the infectious diseases agents: HIV-1, HIV-2, hepatitis virus, West Nile Virus (WNV), Human T-Lymphotropic Virus (HTLV) T. Cruzi, and T. pallidum (syphilis). The result of all these assays must be negative for blood donation.

Technological developments increase the sensitivity and efficiency of the tests. For instance, in 2016, the U.S. FDA approved the Procleix Zika virus assay from Hologic, Inc. and Grifols to screen donated blood. Furthermore, the U.S. FDA approved next-generation sequencing (NGS) technology in 2013. The technology is cheaper and faster than previous DNA analysis methods.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Detailed Segmentation:

Product Insights

On the basis of product, the market is segmented into instruments and reagents. The reagent segment accounted for the largest revenue share of around 73.0% in 2022 and is expected to grow at the fastest CAGR of 12.0% over the forecast period owing to higher accuracy and specificity in detecting the presence and type of various elements in a small sample would drive the market.

Technology Insights

On the basis of technology, the market is segmented into nucleic acid amplification tests, ELISA, CLIA, EIA, NGS, and western blotting. The NAT segment accounted for the largest revenue share of 41.8% in 2022, owing to its high sensitivity and specificity for viral nucleic acid. The test detects nucleic acid earlier than other screening methods and, thus, narrows the window period of HBV, HCV, and HIV. According to the WHO, HIV has claimed 40.1 million lives till now and remains a global health concern with the current transmission in all countries where 1.5 million people attained HIV in 2021.

Regional Insights

North America dominated the market and accounted for the largest revenue share of 39.0% in 2022 owing to the presence of key industry players, increased adoption of the blood screening process, stringent FDA regulations for transfusion, rising infectious disease prevalence, and greater patient affordability are responsible for maintaining its position during the forecast period. The U.S. leads the market due to the local presence of leading players such as Roche Diagnostics, Abbott, and Danaher. One of the reasons for their continued dominance is the presence of well-established R&D infrastructure and favorable reimbursement policies.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global electron microscopes market size was valued at USD 5.05 billion in 2023 and is projected to grow at a CAGR of 8.1% from 2024 to 2030.

• The global ambient assisted living market size was valued at USD 7.36 billion in 2023 and is projected to grow at a CAGR of 26.8% from 2024 to 2030. . 

Key Companies & Market Share Insights

Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach.

For instance, in March 2023,Abbott received U.S Food and Drug Administration (FDA) clearance for a laboratory traumatic brain injury blood test, the first commercially available lab-based test for the assessment of mild traumatic brain injuries (TBIs), commonly referred to as concussions, which will be made widely available to hospitals across the U.S. This test, which is powered by Abbott’s Alinity i laboratory tool, will enable clinicians to evaluate individuals with mild traumatic brain injuries in a timely manner.

Furthermore, in May 2023, Siemens Healthcare introduced Atellica HEMA 570 and 580 next-generation hematology analyzers, which have user-friendly interfaces and can be connected to multiple analyzers to remove workflow barriers and provide high throughput time.

Key Blood Screening Companies:

• Abbott

• Danaher Corporation (Beckman Coulter)

• Becton Dickinson and Company

• Bio-Rad Laboratories, Inc.

• Hoffman-La Roche Ltd.

• Grifols, S.A.

• Ortho-Clinical Diagnostics, Inc.

• Siemens Healthcare GmbH

• Thermo Fisher Scientific, Inc.

• SOFINA s.a (Biomerieux)

Blood Screening Market Segmentation

Grand View Research has segmented the blood screening market by product, technology, and region:

Blood Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Nucleic Acid Amplification Test (NAT)

• ELISA

• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

• Next Generation Sequencing

• Western Blotting

Blood Screening Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagent

• Instrument

Blood Screening Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Sweden

o Norway

o Denmark

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

[healthcaremarketanalysis]

The report "Blood Screening Market by Product (Reagent & Kits, Instrument, Software), Technology (NAT, (Real-Time PCR), ELISA (Chemiluminescence Immunoassay), Rapid Test, Western Blot), End User (Blood Bank, Hospital), & Region - Global Forecast to 2028", is projected to reach USD 3.4 billion by 2028 from USD 2.4 billion in 2023, at a CAGR of 7.2% during the forecast period. Growth in this market is mainly driven by the growing requirement for donated blood, the rising number of blood donations around the world, and the ever-increasing infectious diseases. However, operational barriers and the high cost of Blood screening instruments is likely to hamper the growth of blood screening market.

[aadeshmmr]

The examination of the COVID-19 lock-down's effects on market leaders', followers', and disruptors' revenue is included in the research.

[kkumarsblog]

Marfan Syndrome Market Dynamics and Insights

Marfan syndrome is a genetic disorder that affects connective tissue, impacting various organs such as the heart, blood vessels, bones, and eyes. This condition arises from a mutation in the fibrillin-1 (FBN1) gene, leading to weakened connective tissues. As an autosomal dominant disorder, it can be inherited from an affected parent.

Although Marfan syndrome is a rare disease, its severe complications, especially cardiovascular issues, drive the demand for effective treatments. The Marfan Syndrome Drugs Market is experiencing significant advancements, with pharmaceutical companies actively developing new therapies and treatment strategies to manage the condition.

Marfan Syndrome Market Size and Growth

The global Marfan Syndrome Market Size is expanding due to increased awareness and improved diagnostic capabilities. The estimated prevalence is 1 in 5,000 individuals worldwide, with a slightly higher occurrence in males. Enhanced healthcare infrastructure and accessibility to genetic testing have resulted in a rising number of diagnosed cases, contributing to market growth.

Moreover, the growing focus on genetic disorders, personalized medicine, and biotechnology innovations is fueling expansion. The availability of genetic screening tools has significantly improved early detection and patient management, leading to a steady increase in demand for Marfan syndrome treatments.

Marfan Syndrome Treatment Market: Current Landscape

Since there is currently no cure for Marfan syndrome, treatment focuses on managing symptoms and preventing severe complications, particularly cardiovascular risks. The Marfan Syndrome Treatment Market primarily revolves around:

Beta-Blockers & ARBs: Drugs like propranolol and losartan are widely used to control blood pressure and slow aortic dilation, reducing the risk of aortic dissection or rupture.

Surgical Interventions: In cases of significant aortic enlargement, procedures such as aortic root replacement or valve repair are necessary to prevent life-threatening complications.

Supportive Therapies: Treatments addressing skeletal abnormalities (such as scoliosis) and ocular conditions (like lens dislocation) help improve the quality of life for Marfan patients.

With the rising demand for targeted therapies, pharmaceutical companies are investing in novel drug development to better manage the disorder.

Marfan Syndrome Companies and Drug Developments

Several pharmaceutical companies are at the forefront of research and development in the Marfan Syndrome Drugs Market, focusing on both symptom management and gene-targeted therapies. Some key players include:

Vertex Pharmaceuticals – Exploring treatments for genetic disorders, including Marfan syndrome.

Bristol-Myers Squibb – Known for its leadership in cardiovascular therapies, contributing significantly to Marfan syndrome drug development.

Novartis – Investigating treatments for connective tissue disorders, with promising research in the pipeline.

Sanofi – Actively researching gene therapies and drugs targeting cardiovascular complications of Marfan syndrome.

Emerging Therapeutic Approaches:

Lozartan (Losartan): A prominent Angiotensin Receptor Blocker (ARB) that has shown potential in reducing aortic dilation and slowing disease progression.

Gene Therapy: Advances in CRISPR and other gene-editing technologies offer potential future treatments targeting the FBN1 mutation directly.

Future Outlook of the Marfan Syndrome Market

The Marfan Syndrome Market Size is expected to grow due to increased R&D investments, regulatory support for orphan drug designations, and the emergence of combination therapies. Companies are developing new drug formulations and multimodal treatment strategies that integrate beta-blockers, ARBs, and gene-based therapies to enhance patient outcomes.

Latest Reports Offered By Delveinsight

Uveal Neoplasms Market | Venous Stenosis Medical Devices Market | Venous Thromboembolism Market | Wilson’s Disease Market | Acute Myeloid Leukemia Market | Anemia In Chronic Kidney Disease Market | Carcinoid Tumor Syndrome Market | Cardiovascular Imaging Equipment Market | Dermal Mycosis Market | Erythropoietic Protoporphyria Market | Gastroesophageal Adenocarcinoma Market | Gene And Cell Therapies Targeting Cns Disorders Market | Hemophilia With Inhibitor Market | Hyperparathyroidism Market | Iron Overload Syndrome Market | Ly3454738 Drug Insight | Necrotizing Enterocolitis Market | Nephropathic Cystinosis Market | Obstructive Sleep Apnea Market | Oncolytic Virus Cancer Therapy Pipeline | Recurrent Blood Clots Market | Relapsing Multiple Sclerosis Market | Rhinosinusitis Market | Sarcopenia Market 

About DelveInsight

DelveInsight is a market research and consulting firm specializing in life sciences and healthcare. We deliver valuable insights to help pharmaceutical, biotechnology, and medical device companies succeed in a competitive and rapidly changing industry.

Contact InformationKanishk Email: kkumar@delveinsight.com

[businessindustry]

At-Home Testing Market Global Opportunities | Regions and Growth Status by 2032

The Reports and Insights, a leading market research company, has recently releases report titled “At-Home Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global At-Home Testing Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the At-Home Testing Market?

The global at-home testing market was valued at US$ 7.2 Billion in 2023 and is expected to register a CAGR of 4.2% over the forecast period and reach US$ 10.4 Bn in 2032.

What are At-Home Testing?                                                                                                                                             

At-home testing refers to medical or diagnostic tests that individuals can conduct independently, without the supervision of healthcare professionals or the need for a laboratory. These tests are designed to be convenient and accessible, offering quick results for monitoring various health conditions or parameters from the comfort of one's home. At-home testing kits cater to diverse needs such as screening for infectious diseases, managing chronic conditions like diabetes, assessing fertility, and detecting genetic predispositions. Technological advancements have improved the accuracy and reliability of these tests, making them increasingly favored for proactive health monitoring and early detection.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2349

What are the growth prospects and trends in the At-Home Testing industry?

The at-home testing market growth is driven by various factors and trends. The at-home testing market is growing rapidly, fueled by a rising consumer preference for convenient and accessible diagnostic solutions. These tests enable individuals to monitor their health independently, offering a broad range of applications including screening for infectious diseases, managing chronic conditions, evaluating fertility, and genetic testing. Advancements in technology have enhanced the accuracy, reliability, and user-friendliness of at-home testing kits, driving their popularity for proactive health monitoring and early detection. North America, Europe, and Asia-Pacific are key regions driving market growth, characterized by competitive dynamics among established companies and ongoing innovations in test development and distribution. Hence, all these factors contribute to at-home testing market growth.

What is included in market segmentation?

The report has segmented the market into the following categories:

By Product

Digital Monitoring Instruments

Cassettes

Midstream

Strips

Cups

Dip Cards

Test Panels

Sample collection kits

Others

By Application

Blood Glucose Testing

Pregnancy & Fertility Testing

Cancer Testing

STD/ STI Testing

Testosterone

Drug Abuse Testing

Cholesterol Testing

Thyroid Testing

Others

North America

United States

Canada

Europe

Germany

United Kingdom

France

Italy

Spain

Russia

Poland

Benelux

Nordic

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

ASEAN

Australia & New Zealand

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

Saudi Arabia

South Africa

United Arab Emirates

Israel

Rest of MEA

Who are the key players operating in the industry?

The report covers the major market players including:

Becton, Dickinson and Company

Abbott

ACCESS BIO

CELLTRION INC

Siemens Healthcare GmbH

ACON Laboratories Inc

ARKRAY, Inc, F

Hoffmann-La Roche Ltd

OraSure Technologies Inc

Quest Diagnostics

Bionime Corporation

Btnx Inc

iHealth Labs Inc

InBios International, Inc. USA

Everlywell

LetsgetChecked

View Full Report: https://www.reportsandinsights.com/report/At-Home Testing-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: sales@reportsandinsights.com Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1

[industrynewsupdates]

Blood Screening Market Key Companies, Growth and Forecast Report, 2030

The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. 

Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.

The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Blood Screening Market Report Highlights

• The reagent segment accounted for the largest revenue share of around 73.0% in 2022 and is expected to grow at the fastest CAGR of 12.0% over the forecast period.

• North America dominated the market and accounted for the largest revenue share of 39.0% in 2022 owing to the presence of key industry players, increased adoption of the blood screening process, stringent FDA regulations for transfusion, rising infectious disease prevalence, and greater patient affordability are responsible for maintaining its position during the forecast period.

• Asia Pacific is expected to grow at the fastest CAGR of 13.5% over the forecast period owing to increasing awareness about blood donation, rising patient affordability, and the focus of key industry players on emerging countries in the region.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global sentinel node biopsy market size was estimated at USD 717.8 million in 2023 and is projected to grow at a CAGR of 7.0% from 2024 to 2030. 

• The global market for endoscopy operative devices reached a value of USD 10.34 billion in 2023 and is projected to grow at a CAGR of 5.3% from 2024 to 2030. 

Blood Screening Market Segmentation

Grand View Research has segmented the blood screening market by product, technology, and region:

Blood Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Nucleic Acid Amplification Test (NAT)

• ELISA

• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

• Next Generation Sequencing

• Western Blotting

Blood Screening Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagent

• Instrument

Blood Screening Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Sweden

o Norway

o Denmark

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

[healthcaremarketanalysis]

Blood Screening Market worth $3.4 billion by 2028

Blood Screening Market in terms of revenue was estimated to be worth $2.4 billion in 2023 and is poised to reach $3.4 billion by 2028, growing at a CAGR of 7.2% from 2023 to 2028 according to a new report by MarketsandMarkets™. Growth in this market is mainly driven by the growing requirement for donated blood, the rising number of blood donations around the world, and the ever-increasing infectious diseases. However, operational barriers and the high cost of Blood screening instruments is likely to hamper the growth of blood screening market.

Download an Illustrative overview:

Browse in-depth TOC on "Blood Screening Market"

189 - Tables

45 - Figures

220 – Pages

The Reagents & Kits segment is expected to account for the largest share in 2022.

Based on product, the blood screening market is segmented into reagents & kits, instruments, and software & services. Increase in demand and continuous use of the reagents and kits during blood transfusion processes, post blood donations is responsible for the large segment of this segment.

Nucleic Acid Test segment aimed the highest share during the forecast period

The blood screening market is segmented into nucleic acid tests (NAT), serology/immunoassay, rapid tests, western blot assays, and next-generation sequencing (NGS). In 2022, the nucleic acid test (NAT) segment accounted for the largest share of the blood screening market. From all the other technologies, NAT provides high precision, sensitivity and accuracy for blood screening and therefore, holds the largest share.

North America has the upper hand in the global Blood screening market

By regional segmentation, the blood screening market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East Africa. North America has the largest share and is continuing to dominate the blood screening market. The factors responsible for the large share of North America in this market are the increasing prevalence of infectious diseases, rising awareness in blood donations, and the growing healthcare system that is highly developed in the US and Canada.

Request Sample Pages:

Blood Screening Market Dynamics:

Drivers:

Increasing number of blood donations worldwide

Restraints:

Alternative technologies

Opportunities:

Emerging markets

Challenge:

High cost of blood screening technologies

Key Market Players:

The major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Grifols (Spain), Abbott Laboratories, Inc. (US), Bio-Rad Laboratories, Inc. (US), Danaher (Beckman Coulter, Inc.) (US), bioMérieux (France),  Hologic (US), Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company (US), DiaSorin (Italy), Siemens Healthineers (Germany), QuidelOrtho Corporation (US), Merck KGaA (Germany), Revvity (Earlier known as PerkinElmer Inc.) (US), Bio-Techne Corporation (US), GFE (Germany), Trinity Biotech (Ireland), Mindray (China), Maccura Biotechnology Co., Ltd. (China), Immucor, Inc. (US), Cellabs (Australia), Abnova Corporation (Taiwan), Enzo Biochem, Inc. (US), J. Mitra & Co. Pvt. Ltd. (India) and Tulip Diagnostics (India).

Recent Developments:

In February 2023, Thermo Fisher Scientific Inc. (US) acquired TIB Molbiol (Germany), to expand its PCR test portfolio with a wide range of assays for infectious diseases.

In December 2021, Hologic, Inc. (US) launched Panther Trax for high-volume molecular testing.

In May 2021, Beckmann Coulter (US) launched SARS-CoV-2 IgG.

In September 2021, Roche Diagnostics (Switzerland) acquired TIB Molbiol Group (Germany). This acquisition will enhance Roche's broad portfolio of molecular diagnostics solutions with a wide range of assays for infectious diseases, such as identifying SARS-CoV-2 variants.

Inquiry Before Buying:

Blood Screening Market Advantages:

Early Disease Detection: Blood screening allows for the early detection of various diseases, including infections, cancers, and chronic conditions. Early diagnosis often leads to more effective treatment and improved patient outcomes.

Preventative Medicine: It enables preventative measures by identifying risk factors and potential health issues before they become serious. This proactive approach can lead to better health management and reduced healthcare costs.

Transfusion Safety: Blood screening is vital in ensuring the safety of blood transfusions. It screens for infectious agents like HIV, hepatitis, and syphilis, minimizing the risk of transmitting diseases through donated blood.

Population Health Management: Blood screening data can be analyzed on a population level, helping healthcare systems identify trends, allocate resources more effectively, and develop targeted public health interventions.

Personalized Medicine: Advances in blood screening techniques, such as genetic testing, allow for personalized treatment plans tailored to an individual's genetic makeup, improving the effectiveness of therapies and reducing adverse reactions.

Research and Drug Development: Blood screening plays a pivotal role in clinical trials and drug development, providing insights into treatment efficacy, patient response, and biomarker identification.

Point-of-Care Testing: Point-of-care blood screening devices enable rapid diagnostics in diverse settings, from clinics to remote areas, facilitating timely medical interventions and reducing the burden on healthcare facilities.

Healthcare Efficiency: Automating blood screening processes increases efficiency, reduces human error, and speeds up results, allowing healthcare providers to make quicker and more informed decisions.

Global Health: Blood screening contributes to global health efforts by identifying and controlling infectious diseases, making it an essential tool in disease surveillance and outbreak management.

Improved Quality of Life: Ultimately, the blood screening market's advantages contribute to an overall improvement in the quality of life for individuals and communities, promoting better health and well-being.

In summary, the blood screening market's advantages encompass early detection, preventative care, safety, personalized medicine, research, and healthcare efficiency, all of which have a profound impact on healthcare outcomes and public health.

Related Reports:

[credenceresearchdotblog]

The Hemostasis Testing Systems Market is projected to grow from USD 2,161.30 million in 2024 to USD 3,444.78 million by 2032, with a compound annual growth rate (CAGR) of 6%.Hemostasis testing systems are integral to medical diagnostics, enabling the assessment of blood clotting processes to identify coagulation disorders, monitor anticoagulant therapies, and guide surgical interventions. The global market for these systems has been experiencing significant growth, driven by technological advancements, an aging population, and an increasing prevalence of bleeding disorders.

Browse the full report at https://www.credenceresearch.com/report/hemostasis-testing-systems-market

Market Overview

As of 2024, the global hemostasis testing systems market was valued at approximately USD 2.15 billion. Projections indicate that this market will reach around USD 3.05 billion by 2031, reflecting a compound annual growth rate (CAGR) of 5.1% during the forecast period from 2024 to 2031. citeturn0search5 This upward trajectory underscores the escalating demand for efficient and accurate hemostasis diagnostics.

Key Market Drivers

Rising Prevalence of Bleeding Disorders: Globally, there has been an increase in bleeding disorders such as hemophilia and von Willebrand disease. Early diagnosis and intervention are crucial, propelling the demand for advanced hemostasis testing systems. citeturn0search1

Technological Advancements: The integration of automation, artificial intelligence (AI), and machine learning (ML) into hemostasis testing has enhanced the accuracy and efficiency of diagnostics. Point-of-care testing systems have become more prevalent, offering rapid results and facilitating immediate clinical decisions. citeturn0search1

Aging Population: The global increase in the elderly population has led to a higher incidence of age-related coagulation disorders, thereby boosting the need for hemostasis testing.

Awareness and Early Diagnosis: Growing awareness about bleeding disorders and the importance of early diagnosis have encouraged regular screenings, further driving market growth.

Challenges and Opportunities

Despite the positive outlook, the hemostasis testing systems market faces certain challenges:

High Costs: Advanced hemostasis testing systems and reagents can be expensive, potentially limiting adoption, especially in developing regions.

Lack of Skilled Professionals: Performing complex hemostasis tests requires specialized training. A shortage of skilled personnel can hinder market growth.

Regulatory Hurdles: Stringent regulatory requirements for product approvals can delay the introduction of new technologies.

However, these challenges also present opportunities:

Market Expansion: There is potential for growth in untapped markets, particularly in developing regions with a rising prevalence of bleeding disorders.

Technological Innovation: Collaborations between manufacturers and research institutes can lead to the development of innovative hemostasis testing systems, integrating AI and ML to enhance diagnostic accuracy.

Personalized Medicine: The increasing adoption of personalized medicine and targeted therapies creates a demand for specialized hemostasis testing systems tailored to individual patient needs.

Key Player Analysis:

Abbott Laboratories

Haemonetics Corporation

Siemens Healthcare GmbH

BioMarin Pharmaceutical, Inc.

Sysmex

Grifols, S.A.

Roche Diagnostics Limited

Beckman Coulter, Inc.

Nihon Kohden Corporation

Werfen

Segments:

Based on Application Type:

Hemophilia

Von Willerbrand Disease

Acquired Bleeding Disease

Based on End Use:

Hospitals

Academic Institutions

Hemostasis Testing Systems

Based on the Geography:

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/hemostasis-testing-systems-market

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

[deshpandeisha]

Introduction to Biosensors: Principles and Applications

The global biosensors market size was USD 25.5 Billion in 2021 and is expected to register a revenue CAGR of 8.0% during the forecast period, according to latest analysis by Emergen Research. Increasing application of biosensors in agriculture and healthcare sectors and emergence of nanotechnology-based biosensors are factors projected to support market revenue growth between 2021 and 2030. In addition, rising prevalence of chronic disease such as diabetes, cardiovascular disease, and others globally and growing acceptance of biosensors by diabetics for glucose monitoring are factors contributing to revenue growth of the market. Significant advancements in biosensor technology have eased the process of blood glucose level monitoring in patients, especially in older adults, which has helped in the management of diabetes mellitus.

Other benefits of biosensors include Point of Care (POC) glucose testing and non-invasive glucose monitoring systems among others, which are expected to boost growth of the market during the forecast period. Biosensors are also being used in maternity and fertility testing, and Biosensor-based In-Vitro Diagnostic (IVD) devices are fast becoming excellent alternative tools due to the various advantages this offers. This approach offers a major advantage over conventional detection systems in medicines for an early diagnosis, enables proper screening of targeted population, and also for assessing the efficiency of a specific therapy.

Get Download Pdf Sample Copy of this Report@ https://www.emergenresearch.com/request-sample/42

Competitive Terrain:

The global Biosensors industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.

The leading market contenders listed in the report are:

Abbott, Medtronic, Bio-Rad Laboratories, Inc., Cytiva, LifeScan IP Holdings, LLC, Nova Biomedical, Universal Biosensors, AgaMatrix, PHC Holdings Corporation, ACON Laboratories, Inc

Key market aspects studied in the report:

Market Scope: The report explains the scope of various commercial possibilities in the global Biosensors market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.

Competitive Outlook: The leading companies operating in the Biosensors market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.

Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Biosensors market.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now)@ https://www.emergenresearch.com/request-discount/42

Market Segmentations of the Biosensors Market

This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Biosensors market on the basis of product, application, and region:

Segments Covered in this report are:

Product Outlook (Revenue, USD Billion; 2019–2030)

Wearable

Non-wearable

Technology Outlook (Revenue, USD Billion; 2019–2030)

Electrochemical

Optical

Piezoelectric

Thermal

Nanomechanical

Application Outlook (Revenue, USD Billion; 2019–2030)

Healthcare

Agriculture

Bioreactor

Food Toxicity

Others

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/biosensors-market

Major Geographies Analyzed in the Report:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

ToC of the report:

Chapter 1: Market overview and scope

Chapter 2: Market outlook

Chapter 3: Impact analysis of COVID-19 pandemic

Chapter 4: Competitive Landscape

Chapter 5: Drivers, Constraints, Opportunities, Limitations

Chapter 6: Key manufacturers of the industry

Chapter 7: Regional analysis

Chapter 8: Market segmentation based on type applications

Chapter 9: Current and Future Trends

Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-for-customization/42

About Us:

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Visit for More Insights: https://www.emergenresearch.com/insights

Explore Our Custom Intelligence services | Growth Consulting Services

Trending Titles: Geocell Market | Pancreatic Cancer Treatment Market

Latest Report:  Ceramic Tiles Market | Life Science Analytics Market